Keene & Associates Inc. Raises Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Keene & Associates Inc. boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 27.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,230 shares of the company’s stock after purchasing an additional 6,285 shares during the quarter. Keene & Associates Inc.’s holdings in Elanco Animal Health were worth $354,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after acquiring an additional 4,361,799 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Elanco Animal Health during the third quarter valued at approximately $19,708,000. Assenagon Asset Management S.A. lifted its holdings in shares of Elanco Animal Health by 363.1% during the third quarter. Assenagon Asset Management S.A. now owns 1,548,506 shares of the company’s stock valued at $22,748,000 after purchasing an additional 1,214,123 shares during the last quarter. Private Management Group Inc. boosted its position in shares of Elanco Animal Health by 63.4% in the 4th quarter. Private Management Group Inc. now owns 2,357,142 shares of the company’s stock worth $28,545,000 after purchasing an additional 914,808 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new stake in shares of Elanco Animal Health in the 3rd quarter worth approximately $9,969,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

ELAN stock opened at $11.32 on Wednesday. The company has a market cap of $5.59 billion, a P/E ratio of 28.29, a price-to-earnings-growth ratio of 2.53 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 1 year low of $10.77 and a 1 year high of $18.80. The stock’s fifty day moving average price is $11.88 and its 200-day moving average price is $13.13.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Finally, UBS Group started coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $16.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.